News Center
LIZHU's 2023 S&P ESG score has been further improved, leading among global peers.
Release time:
2023-12-05
Recently, the S&P Global Corporate Sustainability Assessment announced the 2023 environmental, social, and governance (ESG) scoring results. As of December 4, 2023, the S&P ESG score of Livzon Pharmaceutical Group increased from 42 points in 2022 to 65 points, a year-on-year growth of 55%, achieving a score increase for two consecutive years. Currently, Livzon Pharmaceutical Group's S&P CSA score exceeds that of 95% of participating pharmaceutical companies worldwide.
In 2023, Livzon Pharmaceutical Group was also rated MSCI ESG AAA, Wind ESG AA, "2023 Top 20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies," "2023 Annual Wind Top 100 Best Practices of Chinese Listed Companies in ESG," and many other honors. The steady improvement of the S&P ESG score this year further highlights the outstanding results of Livzon Pharmaceutical Group's ESG governance work, which has received widespread recognition and affirmation globally.
The level of ESG governance is currently an important reference standard for global investors to measure the sustainability and social responsibility of listed companies, and the performance of ESG ratings intuitively reflects the company's ESG governance level. Livzon Pharmaceutical Group always adheres to the vision of "being a leader in the pharmaceutical industry," with the mission of "putting patient quality of life first," placing great importance on corporate ESG management work, establishing an ESG governance structure with the board of directors as the highest decision-making body, and incorporating ESG assessment indicators into the personal performance evaluation of ESG working group members, thus creating a compensation mechanism linked to sustainable development. Through top-down policy implementation and effective ESG management and improvement actions, a solid development core for the group's sustainable development work has been established.
About the S&P Global Corporate Sustainability Assessment
In 2023, approximately 13,000 companies worldwide were invited to participate in the S&P Global Corporate Sustainability Assessment. The S&P Global Corporate Sustainability Assessment ("CSA") is one of the largest annual assessments of corporate sustainability practices globally. By quantifying and scoring various ESG management and performance indicators of companies, it comprehensively reflects the level of ESG management and information disclosure of companies, serving as an important basis for global investors' investment decisions and data analysis. The CSA covers 62 different industry-specific sustainability standards, characterized by comprehensive indicators, detailed granularity, strict standards, and transparent data, effectively identifying companies that actively respond to sustainability opportunities and challenges. It is an important basis for companies to be selected for the Dow Jones Sustainability Index (DJSI) and other S&P ESG series indices. For the pharmaceutical industry, S&P has set the scoring weights for the environmental dimension, social dimension, governance, and economic dimension at 13%, 42%, and 45%, respectively.
Related Information